Long-term follow-up of a phase I/II trial of radiation dose escalation by simultaneous integrated boost for locally advanced esophageal squamous cell carcinoma
Esophageal cancer is one of the most common malignancies with high cancer-related death rate over the world. China possesses the top prevalence and mortality of esophageal squamous cell carcinoma (ESCC). ESCC has a poor prognosis due to high risks of local recurrence and distant metastasis. About one-half of patients present with locally advanced stage at the time of diagnosis. Since (Radiation Therapy Oncology Group) RTOG 85-01, concurrent chemoradiotherapy (CRT) has become the standard treatment of locally advanced esophageal cancer[1,2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Ying Zhang, Wen Feng, Lan-Ting Gao, Xu-Wei Cai, Qi Liu, Zheng-Fei Zhu, Xiao-Long Fu, Wen Yu Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Esophagus Cancer | Radiation Therapy | Radiology | Skin Cancer | Squamous Cell Carcinoma